本文選題：β-微精漿蛋白 + 前列腺癌��； 參考：《天津醫(yī)科大學(xué)》2014年碩士論文

【摘要】：目的：通過檢測前列腺癌(PCa)患者血清MSMB的表達(dá)情況,研究其與前列腺癌進(jìn)展的關(guān)系,探討其在前列腺癌患者中的臨床應(yīng)用價值,為前列腺癌的診斷以及惡性行為評估提供新的標(biāo)志物,以及理論依據(jù)和研究基礎(chǔ)。 方法：我們以164人作為研究對象,采用ELISA方法檢測97例前列腺癌患者(實(shí)驗(yàn)組)和67例良性前列腺增生患者(對照組)的血清MSMB含量,比較兩組人群血清MSMB之間的差異,并分析不同臨床分期和病理分級(Gleason評分)前列腺癌患者血清MSMB含量之間的差異,以及在不同PSA水平前列腺癌患者血清MSMB含量之間的差異。 結(jié)果：ELISA檢測發(fā)現(xiàn),前列腺癌患者血清中MSMB的濃度[(6.52±2.99)ng/mL]明顯低于良性前列腺增生患者血清中MSMB的濃度[(23.40±15.37)ng/mL](P=0.000)。另外,前列腺癌臨床分期≤T2a、=T2B、≥T2c的血清MSMB含量分別為(8.72+1.06)ng/mL、(6.91±1.62)ng/mL、(2.21±1.55)ng/mL(P均0.05)；前列腺癌病理分級Gleason評分≤6、=7、≥8的血清MSMB含量分別為(8.70±1.35)ng/mL、(6.31±0.78)ng/mL、(2.02±1.31)ng/mL(P均0.05),說明不同臨床分期和病理分級前列腺癌患者血清MSMB的含量存在明顯差異。但前列腺癌PSA10ng/mL(10-20) ng/mL、20ng/mL的血清MSMB含量分別為(6.52±2.86)ng/mL、(7.87±2.26) ng/mL、(5.78±3.23) ng/mL(P=0.052),說明不同PSA水平前列腺癌患者血清MSMB的含量無明顯差異。 結(jié)論：血清MSMB在前列腺癌的臨床診斷方面具有重要的價值,是診斷前列腺癌的一種較理想生物學(xué)標(biāo)記。前列腺癌患者血清MSMB含量明顯低于良性前列腺增生患者,且其隨前列腺癌臨床分期和Gleason評分的增高而降低,可大致判斷前列腺癌的浸潤度和惡性度,可用于前列腺癌的預(yù)后評估。
[Abstract]:Objective: to study the relationship between the expression of serum MSMB and the progression of prostate cancer in patients with prostate cancer (PCA), and to explore its clinical application value in patients with prostate cancer. To provide a new marker for the diagnosis of prostate cancer and the evaluation of malignant behavior, as well as theoretical basis and research basis. Methods: the serum MSMB levels of 97 patients with prostate cancer (experimental group) and 67 patients with benign prostatic hyperplasia (control group) were measured by ELISA method. The difference of serum MSMB between the two groups was compared. The difference of serum MSMB content in prostate cancer patients with different clinical stage and pathological grade (Gleason score) and the difference of serum MSMB content among prostate cancer patients with different PSA level were analyzed. Results the concentration of MSMB in serum of prostate cancer patients [6.52 鹵2.99)ng/mL] was significantly lower than that of patients with benign prostatic hyperplasia [23.40 鹵15.37)ng/mL]. In addition, The serum MSMB levels of patients with prostate cancer 鈮，

本文編號：1837373